Main Catalog

Found 80

Sort by

Member Free

Non-Member Free

The Impact of Value-Based Care on Inflammatory Bowel Disease - Home Study

Contact Hours: 1.5. Inflammatory bowel disease (IBD) affects approximately 1.3 million U.S. adults and creates a heavy psychological burden for patients because symptoms can occur spontaneously.

IBD

Member Free

Non-Member Free

Opioid Use Disorder: Emerging Best Practices for Payer and Clinician Management of Patient Care - Home Study

Addressing opioid use disorder (OUD) is a top concern for public health improvement. It is important to keep up with current treatment options to optimally treat patients, and while treatments vary by patient, a collaborative team environment is necessary for holistic care management.

Opioid

Member Free

Non-Member $30.00

Experience and Lessons Learned in Biosimilar Uptake

Contact Hours: 1.5. Although biosimilars have been on the market for some time, payers continue to face many challenges in implementation.

Biosimilars

Member Free

Non-Member $30.00

Medical Oncology Drug Cost Trends and Innovative, Practical Payer Management Strategies

Contact Hours: 1.5. Medical oncology drugs represent 35 to 47% percent of total medical benefit drug spend.

Oncology

Member Free

Non-Member $30.00

Coverage and Reimbursement for High Cost Curative Therapeutics: Does a Solution Exist?

Contact Hours: 1.5. More and more, managed care organizations are straddling the line between making new, innovative therapies available to their patients and ensuring they can cover the costs of these therapies.

Drug Pricing

Member Free

Non-Member $30.00

Using Online Real-World Evidence Tools to Enhance Formulary Decision-Making

Contact Hours: 1.5. Evidence to determine comparative effectiveness and safety requires the use of real-world data (RWD) to create real-world evidence (RWE) that ultimately is used to inform policy decisions.

Real World Evidence

Member Free

Non-Member $30.00

Specialty Pharmaceuticals in Development

Contact Hours: 1.25. Over the last several years, approvals of specialty pharmaceuticals have far outpaced those of traditional drugs. It is anticipated that this trend will continue.

Specialty Pharmacy

Member Free

Non-Member $30.00

A Path Forward: Medicaid Accountable Care Organization Implementation

Contact Hours: 1.5. While a dozen states have implemented new Accountable Care Organization (ACO) Medicaid models, another 12 are in the planning phases.

Accountable Care Organization

Member Free

Non-Member $30.00

End of an Era: Lessons Learned from 2018 CMS Audits, and Prep for the Future

Contact Hours: 1.5. Ready for that upcoming 2019 audit? Do you know how to prepare? If your answer is no, join this session to hear how health plans prepare for their audits and address corrective actions, as lessons learned from the 2018 audit season are discussed.

CMS

Member Free

Non-Member $30.00

Federal and State Legislative and Regulatory Update

Contact Hours: 1.5. This must-attend session will bring you timely updates on the latest federal and state legislative and regulatory actions of interest to managed care and specialty pharmacy professionals.

Law

Member Free

Non-Member $30.00

A State Medicaid’s Experience Implementing an Oversight Program for Behavioral Health Medications in Publicly Insured Youth

Contact Hours: 1.5. Utilization of behavioral health medications in the pediatric population has increased in recent years, a trend that has generated major concern given the limited supporting evidence.

Patient Care

Member Free

Non-Member $30.00

The CAR-T Carve Out: Reevaluating CAR-T Reimbursement and Long Term Outcomes

Contact Hours: 1.5. The CAR-T treatment process is complex and involves a multidisciplinary team, with intense coordination between patients, treating providers, manufacturers and payers.

Hospital/Health Systems

Member Free

Non-Member $30.00

Visions of a US Value-Based Health Care System

Contact Hours: 1.25. Value—a word of great promise and ambiguity—continues to chisel and sculpt the national health care system at large.

Hospital/Health Systems

Member Free

Non-Member $30.00

Understanding MACRA and the Impact of Medication Use on Quality Payment Program Performance Measures

CPE 1.5 | 1.5 AMA PRA | Nurse 1.5 Contact Hours | As part of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), providers have two options to participate in Part B that will determine how they are reimbursed through the new Quality Payment Program— (APMs) or (MIPS).

Hospital/Health Systems

Member Free

Non-Member $30.00

The Present and Future of Oncology Care Management

Contact Hours: 1.25. Participants should claim continuing pharmacy education (CPE) credit for this home study activity, only if they have not claimed credit for the live activity presented at AMCP Annual Meeting 2017.

Oncology

Member Free

Non-Member $30.00

The New Era of Precision Medicine in Oncology

Contact Hours: 1.5. Advances in cancer genomics have paved the way for a new era of precision medicine in oncology.

Oncology

Member $15.00

Non-Member $30.00

The Current Status of Safe Harbor Protection for Rebates: Is the End Near?

Contact Hours: 1.25: The Department of Health and Human Services (HHS) Office of Inspector General recently introduced a sweeping proposal that would eliminate safe harbor protections in the Anti-Kickback Statute for rebates.

Rebates

Member $15.00

Non-Member $30.00

The Current State of Value-Based Contracting

Contact Hours 1.25. Value-based contracting (VBC) has shown significant promise as an emerging model that rewards value rather than volume in health care.

Value-Based Contracting

Member $15.00

Non-Member $30.00

The Copay Card Conundrum: Examining the Usage, Regulation, and Management of Direct-to-Consumer Funding Programs

Contact Hours: 1.25. Drug manufacturer copay cards and coupons have been facing increasing criticism and scrutiny by legislators at the federal and state level, as well as by health plan payers, pharmacy benefit managers (PBMs) and employer groups.

Copay Cards

Member Free

Non-Member $30.00

The Basics of Mobile Health (mHealth) and Its Potential Impact

Health IT

Member Free

Non-Member $30.00

Tackling the Opioid Epidemic and Addiction Treatment: A Managed Care Approach

Opioid

Member $15.00

Non-Member $30.00

Strategies for Staying Ahead of Specialty Drug Trends: Focus on the Medical Pharmacy Benefit

Contact Hours 1.25. For the tenth consecutive year, specialty pharmaceutical growth has far exceeded that of traditional drugs.

Medical Pharmacy Benefit

Member Free

Non-Member $30.00

Spotlight on the Oncology Pipeline

CPE 1.5 | 1.5 AMA PRA | Nurse 1.5 Contact Hours | With the recent emphasis and success of immune checkpoint inhibitors for the treatment of various tumor types, it is tempting to assume that the oncology pipeline exclusively focuses on immunotherapies.

Oncology

Member Free

Non-Member $30.00

Specialty Pharmaceuticals in Development 2018

Contact Hours: 1.25. Over the last several years, approvals of specialty pharmaceuticals have far outpaced those of traditional drugs. It is anticipated that this trend will continue.

Specialty Pharmacy

Member Free

Non-Member $30.00

Specialty Pharmaceuticals in Development

Contact Hours: 1.5. Over the last several years, approvals of specialty pharmaceuticals have far outpaced those of traditional drugs.

Specialty Pharmacy

Member $15.00

Non-Member $30.00

Specialty Pharmaceuticals in Development

Contact Hours 1.25. Over the last several years, approvals of specialty pharmaceuticals have far outpaced those of traditional drugs. It is anticipated that this trend will continue.

Specialty Pharmacy

Member $39.00

Non-Member $79.00

Specialty Connect 2018 Bundle!

A dynamic, cutting-edge look at evolving standards of care and emerging therapeutic options for hemophilia— designed for and with industry leaders, experts and Managed care pharmacists operating in the fast-growing specialty sector.

Hemophilia

Member $39.00

Non-Member $79.00

Specialty Connect 2019 Bundle!

Gene therapy is a fascinating field that has the potential to improve the health of millions of patients. Promising advancements using gene therapy technology and techniques are offering hope for many with rare and serious diseases.

Gene Therapy

Member Free

Non-Member $30.00

Real-World Experience Managing Orphan Drugs Across Pharmacy and Medical Benefits

Contact Hours: 1.25. Recently approved drugs for orphan diseases have annual costs ranging from $90,000 to over $1 million, while also having variable value propositions.

Orphan Disease

Member Free

Non-Member $30.00

Rare Disease Therapies: Management Strategies to Pipeline Implications for Health Plans

Contact Hours: 1.5. The drug pipeline contains over 560 therapies in development for rare diseases.

Orphan Disease

Member $15.00

Non-Member $30.00

Pulmonary Arterial Hypertension and the Managed Care Considerations for Formulary Decision-Making

Contact Hours: 1.25. Patients with pulmonary arterial hypertension (PAH) currently have a 60% five-year survival outlook, which has been increasing since the 1980s when it was a 37% five-year outlook.

Pulmonary Arterial Hypertension

Member Free

Non-Member $30.00

Pharmacy Benefit Management—Staying Ahead of Your Competition

Contact Hours: 1.25. Consolidations, acquisitions and partnerships across the health care spectrum have led to a highly competitive pharmacy benefit management (PBM) market.

Pharmacy Benefit Design

Member $15.00

Non-Member $30.00

Perspectives in Hemophilia Management

Contact Hours: 1.0. The treatment of hemophilia has evolved from a one-size-fits-all approach to a highly individualized care approach, and it continues to become more
patient-centered and specific.

Hemophilia

Member $15.00

Non-Member $30.00

Perspectives in Gene Therapy Management

Contact Hours: 1.0. The potential for gene therapy to transform the treatment of a wide variety of health conditions has important implications for many stakeholders.

Gene Therapy

Member Free

Non-Member $30.00

Payer & Manufacturer Communications: What’s Changed & How Does it Impact Managed Care Pharmacy?

Contact Hours: 1.5. FDA released long-awaited draft guidance clarifying the Provisions of FDAMA 114 as updated by Cures 3037, and also outlined its current thinking around preapproval information exchange (PIE).

CMS

Member Free

Non-Member $30.00

Patient-Reported Outcomes: A Primer for Managed Care Pharmacists

Patient Care

Member Free

Non-Member $30.00

More than Meets the Eye–Value-Based Contracts are More Prevalent than We Think

Contact Hours: 1.25. As the U.S. health care system evolves from a volume-driven system to one that rewards value, there is growing interest in value-based payment arrangements.

Value-Based Contracting

Member $15.00

Non-Member $30.00

Medicare Formulary Updates Impact

Contact Hours: 1.25. The Centers for Medicare and Medicaid (CMS) continues to critically evaluate formulary regulations and guidance to help lower drug costs.

Medicare

Member Free

Non-Member $30.00

Medical Benefit Medication Management - Low Hanging Fruit to Complex Strategy

Contact Hours: 1.5. Are you up to speed on the latest industry best practices in managing your medical-benefit medications?

Hospital/Health Systems

Member $15.00

Non-Member $30.00

Measuring Value of an IDN Specialty Pharmacy Therapy Management Program for Biologics

Contact Hours: 1.25: Gene therapy is a promising treatment option for a number of diseases, including inherited disorders, some types of cancer, and certain viral infections. The first gene therapy approvals in the United States occurred in 2017.

IDN

Member Free

Non-Member $30.00

Managing the Health Care Affordability Crisis: Approaches that Benefit Both the Payer and Patient

Hospital/Health Systems

Member $15.00

Non-Member $30.00

Managing Patients with Hemophilia: A Payer’s Perspective

Contact Hours: 1.0. Thanks to significant improvements in the treatment of hemophilia, patients are living longer than ever before, with higher expectations for
near-normal quality of life.

Hemophilia

Member Free

Non-Member $30.00

Managing Orphan Drugs for Rare Diseases: Challenges, Opportunities, and Value Assessment

Contact Hours: 1.5. Managing Orphan Drugs for Rare Diseases: Challenges, Opportunities and Value Assessment.

Orphan Disease

Member Free

Non-Member $30.00

Key Forces Driving Change in Oncology

Contact Hours: 1.25. Oncology practice is changing rapidly as new advances in innovation lead to new evidence and testing requirements, as well as treatment guidelines.

Oncology

Member Free

Non-Member $30.00

Keeping up with Biosimilars: The Latest on Regulation, Utilization, Monitoring, and Pipeline

Biosimilars

Member $15.00

Non-Member $30.00

It’s an ART: Formulary and Drug Use Management Strategies for HIV Medications

Contact Hours: 1.25. As people with HIV age, the focus of disease management places more emphasis on the safety of long-term medication use and managing comorbidities. The advantages of safer, more efficacious medications also come with increased cost.

HIV

Member $15.00

Non-Member $30.00

Introduction to Gene Therapy: Key Terms, Concepts, and International Perspectives

Contact Hours: 1.0 : Gene therapy is an investigational technique that offers exciting promise of curing many debilitating and potentially terminal diseases, such as cystic fibrosis, multiple sclerosis, hemophilia, sickle cell disease, and spinal muscular atrophy.

Gene Therapy

Member Free

Non-Member $30.00

Incorporating Best Practices in Transgender Health Policies and Formulary Development into Your Health Plan

CPE 1.5 | 1.5 AMA PRA | Nurse 1.5 Contact Hours | The Centers for Disease Control and Prevention (CDC) estimates that an increasing number of Americans—currently, 1.4 million adults—identify as transgender.

Hospital/Health Systems

Member Free

Non-Member $30.00

Improving Star Ratings Through Focused Clinical Strategy and Targeted Outreach: Results from a Systematic Approach

Contact Hours: 1.5. Star Ratings continue to evolve as measure specifications, benchmarks and inclusion into the overall calculation continue to change under Medicare.

CMS

Member Free

Non-Member $30.00

Global View of Value Assessment Frameworks: How Does AMCP Format 4.0 Compare?

Value Frameworks

Main Catalog

Error